Payment overview · 2025
General Payments
$206.32
8 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Allen Glick, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · THE VILLAGES, FL · NPI 1275572893
Verified facts
What the public records show
CMS Open Payments records show Michael Allen Glick, M.D. received $206.32 in general payments during 2025 across 8 reported records.
Averitas Pharma Inc. accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $76.47 | 37.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.07 | 20.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.12 | 12.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.85 | 10.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.84 | 10.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.97 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.32 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $76.47 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 82 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 775 | 250 |
| Levothyroxine Sodium | Levothyroxine Sodium | 597 | 170 |
| Lisinopril | Lisinopril | 478 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 417 | 135 |
| Losartan Potassium | Losartan Potassium | 315 | 94 |
| Metformin Hcl | Metformin Hcl | 315 | 96 |
| Simvastatin | Simvastatin | 282 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 252 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 79 |
| Prednisone | Prednisone | 247 | 141 |
| Omeprazole | Omeprazole | 227 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 50 |
| Alprazolam | Alprazolam | 152 | 50 |
| Ezetimibe | Ezetimibe | 150 | 46 |
| Gabapentin | Gabapentin | 140 | 45 |
| Glipizide Er | Glipizide | 135 | 37 |
| Nifedipine Er | Nifedipine | 132 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 36 |
| Allopurinol | Allopurinol | 107 | 33 |
| Sertraline Hcl | Sertraline Hcl | 101 | 29 |
| Synthroid | Levothyroxine Sodium | 99 | 28 |
| Atenolol | Atenolol | 96 | 26 |
| Finasteride | Finasteride | 95 | 28 |
| Potassium Chloride | Potassium Chloride | 95 | 31 |
| Furosemide | Furosemide | 87 | 36 |
| Eliquis | Apixaban | 82 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 53 |
| Trazodone Hcl | Trazodone Hcl | 78 | 27 |
| Carvedilol | Carvedilol | 77 | 21 |
| Lorazepam | Lorazepam | 69 | 22 |
| Lovastatin | Lovastatin | 69 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 22 |
| Tramadol Hcl | Tramadol Hcl | 66 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 26 |
| Montelukast Sodium | Montelukast Sodium | 64 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 15 |
| Glimepiride | Glimepiride | 57 | 17 |
| Azithromycin | Azithromycin | 55 | 42 |
| Terazosin Hcl | Terazosin Hcl | 54 | 18 |
| Meloxicam | Meloxicam | 53 | 20 |
| Cephalexin | Cephalexin | 50 | 38 |
| Jardiance | Empagliflozin | 50 | 13 |
| Benazepril Hcl | Benazepril Hcl | 49 | 14 |
| Metformin Hcl Er | Metformin Hcl | 49 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Warfarin Sodium | Warfarin Sodium | 44 | 14 |
| Valsartan | Valsartan | 43 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Bumetanide | Bumetanide | 41 | 11 |
| Glipizide | Glipizide | 41 | 11 |
| Famotidine | Famotidine | 40 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | 14 |
| Nabumetone | Nabumetone | 34 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 13 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 16 |
| Torsemide | Torsemide | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.32 · 8 records | Averitas Pharma Inc. | ABRYSVO, CAPVAXIVE, COMIRNATY, ELIQUIS, INCEPTIV, JARDIANCE, PREVNAR 20, QUTENZA, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error